Novel immunotherapy for AML using ANT308-Fc3 fusion
Official title: Development of a Novel Immunotherapeutic for Acute Myeloid Leukemia
Funded at Cambium Oncology LLC · NIH-11412657 · Data updated 2026-11-12
A new immune therapy for adults with acute myeloid leukemia aims to boost the body's own T cells to fight AML.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cambium Oncology LLC NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | June 12, 2024 |
| Project end | May 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $1,050,003 |
| NIH project number | 5R44CA285206-03 |
| Project ID | NIH-11412657 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults diagnosed with acute myeloid leukemia whose disease expresses VIP-related immune evasion markers may be eligible in future translational steps or trials.
✕Less likely to help
Patients whose AML does not rely on VIP-mediated immune evasion or who do not meet translational criteria may not benefit.
What this research studies
This grant funds development of a VIP-receptor antagonist, ANT308, fused to an IgG Fc region, to overcome AML's immune evasion. The program uses in silico screening and preclinical testing to improve potency and half-life compared with earlier candidates. If successful, this approach could pave the way for a more effective immunotherapy option for adults with AML and potentially reduce reliance on high-mortality treatments.
Why it matters
Potential benefit: It could lead to a new treatment that restores immune function against AML and improves survival or quality of life.
How similar studies have gone: Previous VIP-receptor antagonist studies showed promise in preclinical AML models, but optimization is needed for clinical use.
Where this research is happening
-
Cambium Oncology LLC
Atlanta, United States Active
Researchers
- Principal investigator: Altman, Gary G. — Cambium Oncology LLC
- Study coordinator: Altman, Gary G.
Related research
Other NIH-funded projects on the same topics.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Interferon-γ plus donor immune cells to fight AML/MDS after partial donor transplant
This project tests a therapy that adds a signaling protein, IFN-γ, with donor immune cells to help treat relapsed AML/MDS after a haploidentical stem cell transplant.
-
Targeting the protein housekeeping system in adult leukemia
Researchers are testing a new approach to treat acute myeloid leukemia by disrupting how AML cells manage their proteins, with the goal of helping patients live longer and healthier lives.
-
Understanding how epigenetic helper proteins drive AML and how to target them
A scientist team is studying how accessory proteins in gene-regulating complexes affect acute myeloid leukemia and whether they can be targeted for safer, more precise therapies.
-
Targeting FLVCR1-enabled choline use in a aggressive AML subtype
A new approach aims to block how a specific leukemia subtype (CG-AML) takes up choline to feed its growth, potentially slowing or stopping the disease.
-
Advancing CD70-targeted CAR-NK Therapy for AML
A patient-focused look at a new cell therapy that uses engineered NK cells to target AML by hitting CD70, aiming to reduce relapse with potentially fewer blood cell problems.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.